Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.3673 EUR
−74.71 M EUR
6.69 M EUR
225.42 M
About Vaxart, Inc. - Common Stock
Sector
Industry
CEO
Steven Lo
Website
Headquarters
South San Francisco
Founded
2004
FIGI
BBG000GGKMP8
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in March 2004 and is headquartered in South San Francisco, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange Vaxart Inc. stocks are traded under the ticker NB11.
We've gathered analysts' opinions on Vaxart Inc. future price: according to them, NB11 price has a max estimate of 7.15 EUR and a min estimate of 2.24 EUR. Watch NB11 chart and read a more detailed Vaxart Inc. stock forecast: see what analysts think of Vaxart Inc. and suggest that you do with its stocks.
NB11 reached its all-time high on Feb 3, 2021 with the price of 21.2000 EUR, and its all-time low was 0.2346 EUR and was reached on Sep 27, 2019. View more price dynamics on NB11 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
Yes, you can track Vaxart Inc. financials in yearly and quarterly reports right on TradingView.
Vaxart Inc. is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
NB11 earnings for the last quarter are −0.05 EUR per share, whereas the estimation was −0.09 EUR resulting in a 40.30% surprise. The estimated earnings for the next quarter are 0.00 EUR per share. See more details about Vaxart Inc. earnings.
Vaxart Inc. revenue for the last quarter amounts to 4.43 M EUR, despite the estimated figure of 1.73 M EUR. In the next quarter, revenue is expected to reach 19.99 M EUR.
NB11 net income for the last quarter is −12.65 M EUR, while the quarter before that showed −15.37 M EUR of net income which accounts for 17.74% change. Track more Vaxart Inc. financial stats to get the full picture.
No, NB11 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 16, 2024, the company has 125.00 employees. See our rating of the largest employees — is Vaxart Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Vaxart Inc. EBITDA is −60.36 M EUR, and current EBITDA margin is −1.07 K%. See more stats in Vaxart Inc. financial statements.
Like other stocks, NB11 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Vaxart Inc. stock right from TradingView charts — choose your broker and connect to your account.